All In Biotech

Drug Trial Radar · NCT07608354

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

A Phase IIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo in Adult Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 326 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

326

Planned (sponsor's estimate)

Start

Jun 11, 2026

Primary completion

Feb 6, 2029

Study completion Feb 6, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Conditions

  • Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Interventions

  • EplontersenDrug

    Eplontersen delivered subcutaneously, once every 4 weeks

  • ALXN2220Biological

    ALXN2220 delivered intravenously, once every 4 weeks

  • PlaceboOther

    Placebo delivered intravenously, once every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cardiopulmonary exercise test peak VO2Time frame: 52 week

Locations

76 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California

  • Research Site

    San Francisco, California

  • Research Site

    Stanford, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Weston, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Boston, Massachusetts

  • Research Site

    Kansas City, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    New York, New York

  • Research Site

    Chapel Hill, North Carolina

  • Research Site

    Durham, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Danville, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Germantown, Tennessee

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Falls Church, Virginia

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Chongqing, China

  • Research Site

    Guangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Créteil, France

  • Research Site

    Marseille, France

  • Research Site

    Rennes, France

  • Research Site

    Toulouse, France

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.